Windtree Therapeutics, Inc. P/S ratio

P/S ratio of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of Windtree Therapeutics, Inc. is 277.53 (as of December 30, 2019)
  • P/S ratio for the quarter ending December 30, 2019 was 277.53 (a 37.01% increase compared to previous quarter)
  • Year-over-year quarterly P/S ratio increased by 2109.09%
  • Annual P/S ratio for 2019 was 277.53 (a 2109.09% increase from previous year)
  • Annual P/S ratio for 2018 was 12.56 (a 256.61% increase from previous year)
  • Annual P/S ratio for 2017 was 3.52 (a -31.94% decrease from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of Windtree Therapeutics, Inc.

Most recent P/S ratioof WINT including historical data for past 10 years.

Interactive Chart of P/S ratio of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 277.53 202.56 85.3 277.53
2018 12.56 7.13 10.92 6.8 12.56
2017 3.52 1.28 1.04 4.69 3.52
2016 5.18 11.9 17.63 15.7 5.18
2015 20.75 20.91 29.5 34.01 20.75
2014 34.82 90.85 120.28 524.62 34.82
2013 320.52 208.44 95.81 0.0 320.52
2012 0.0
2011 0.0 0.0 0.0

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.